- Physical examination
- Cell and tissue study
- Blood tests
- Imaging tests
- Lumbar puncture
The non-hodgkin lymphoma diagnostics market is valued at USD billion in 2021 and is poised to grow at a significant CAGR over 2022â€“2028. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this. Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin's has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos. Recent Market Developments: In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.
Fastest Growing Market
Non-Hodgkin lymphoma (NHL) is a type of malignant lymphoid malignancies that preferentially involve nodes and have unique histological and/or biological properties. A frequent haematological malignancy is non-Hodgkin lymphoma (NHL). NHL incidence rates for men and women in India, adjusted for age, are 2.9/100,000 and 1.5/100,000, respectively. These incidence rates represent around one-fourth of those from North America or Western Europe. In India, the incidence of cancer is many times greater in urban than in rural areas, with the incidence being higher in metropolitan areas and among Indian immigrants, suggesting that urban lifestyles and economic development may raise the prevalence of cancer.
The non-hodgkin lymphoma diagnostics market is projected to expand at a CAGR of x% during the forecast period.
BD, Aspire Medical Innovation, Thermo Fisher Scientific, Medtronic, Merit Medical Systems
Asia Pacific is the fastest-growing region for non-hodgkin lymphoma diagnostics market